Publication | Open Access

A Phase I and Pharmacodynamic Study of AT9283, a Small-Molecule Inhibitor of Aurora Kinases in Patients With Relapsed/Refractory Leukemia or Myelofibrosis

Hematological MalignancyRelapsed/refractory LeukemiaMixed-phenotype Acute LeukemiaReceptor Tyrosine KinaseAurora KinasesCell BiologySmall-molecule InhibitorRadiation OncologyMyeloid Neoplasia